Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX)

Market Closed
8 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
8. 27
+0.47
+6.03%
After Hours
$
8. 26
-0.01 -0.12%
294.72M Market Cap
- P/E Ratio
0% Div Yield
467,227 Volume
- Eps
$ 7.8
Previous Close
Day Range
7.79 8.29
Year Range
1.78 8.45
Want to track KYTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX

NEW ORLEANS, LA / ACCESSWIRE / December 30, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS:KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO").

Accesswire | 11 months ago
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – KYTX

Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) pursuant and/or traceable to the Kyverna's initial public offering conducted on February 8, 2024 (the "IPO"), of the important February 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Accesswire | 11 months ago
Shareholders that Lost Money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that Lost Money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Investors who lost money on Kyverna Therapeutics, Inc. (KYTX) should contact Levi & Korsinsky about pending Class Action - KYTX

Investors who lost money on Kyverna Therapeutics, Inc. (KYTX) should contact Levi & Korsinsky about pending Class Action - KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Accesswire | 11 months ago
Lost Money on Kyverna Therapeutics, Inc. (KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Kyverna Therapeutics, Inc. (KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm

Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.

Accesswire | 11 months ago
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky

Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX

Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
KYTX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

KYTX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO").

Accesswire | 11 months ago
Investors who lost money on Kyverna Therapeutics, Inc.(KYTX) should contact Levi & Korsinsky about pending Class Action - KYTX

Investors who lost money on Kyverna Therapeutics, Inc.(KYTX) should contact Levi & Korsinsky about pending Class Action - KYTX

NEW YORK, NY / ACCESSWIRE / December 29, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Loading...
Load More